Paris, December 2nd 2021
SkinDermic is very proud to announce very good results of the SDK 001 compound in the treatment of Kaposi’s sarcoma. SDK 001 was evaluated on an exploratory proof-of-concept clinical trial evaluating for 3 months SDK 001 in patients presenting severe Kaposi’s sarcoma. The results showed a positive efficacy of SDK 001 on Kapois’s sarcoma-related lesions and lymphedema. SDK 001 was very well tolerated; no patient harbored any side effect during the trial.
SkinDermic owns the exclusive patent and rights on the exploitation of SDK 001 in dermatology. SDK 001 is primaquine repurposed in new indications.